Yanfei Chen

Yanfei Chen

Auto-generated profile, based on publicly available information

Yanfei Chen

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2018 in Separation Science and Technology
Verified
Journal Article
Closed access
YCYanfei Chen
Yanfei Chen
XZXiupin Zhang
Xiupin Zhang
QSQing Shi
Qing Shi
GZGuofan Zhang
Guofan Zhang
QLQi Li
Qi Li
The effects of configuration of the stirred tank and energy input on the flotation performance of nickel ores were systematically investigated in this paper. Flotation tests revealed that the stirred tanks with two impellers had an advantage over those with one impeller in intensifying agitation pretreatment, and the higher agitation speed led to a better flotation performance of nickel ores. It was also found that with baffles in the stirred tanks, the flotation grade was higher than that without baffles. Besides, the energy supplied to the system significantly influenced the flotation recovery, indicating that if the energy consumption of the agitation pretreatment is ideal, the improvement of the flotation efficiency can be achieved. Also, data from full-scale operations backed up these results.

1 March 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
YWYaBing Wang
YaBing Wang
YMYan Ma
Yan Ma
PGPeng Gao
Peng Gao
YCYanfei Chen
Yanfei Chen
BYBin Yang
Bin Yang
LJLiqun Jiao
Liqun Jiao

6 May 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
QXQianhan Xie
Qianhan Xie
JNJiali Ni
Jiali Ni
WGWanru Guo
Wanru Guo
CDCheng Ding
Cheng Ding
FWFengjiao Wang
Fengjiao Wang
YCYanfei Chen
Yanfei Chen
Gut microbiota dysbiosis plays a role in the pathogenesis of post-acute coronavirus disease (COVID-19); however, the long-term recovery of the gut microbiota following SARS-CoV-2 infection remains insufficiently understood. In this study, 239 fecal samples were collected from 87 COVID-19 patients during the acute phase, and at 6 months, 1 year, and 2 years post-discharge. An additional 48 fecal samples from non-COVID-19 controls were also analyzed. Gut enterotypes were determined through 16S rRNA sequencing, and dynamic changes from the acute phase through recovery were assessed. Correlations between enterotypes and clinical characteristics were also examined. Two distinct enterotypes were identified: a Blautia-dominated enterotype (Enterotype-B) and a Streptococcus-dominated enterotype (Enterotype-S). Species diversity and richness were significantly higher in Enterotype-B. Enterotype-S, associated with inflammation, was more prevalent during the acute phase. Six months post-discharge, the ratio of Enterotype-B to Enterotype-S approached normal levels. Patients with Enterotype-S at admission had a higher incidence of severe cases during hospitalization and a longer duration of nasopharyngeal viral shedding compared with those with Enterotype-B. Furthermore, at 6 months post-discharge, residual pulmonary Computed Tomography (CT) abnormalities were more common in patients with Enterotype-S (55%) than in those with Enterotype-B (20%, P = 0.046). An index, B/S, representing the ratio of Blautia and Bifidobacterium to Streptococcus, was introduced and found to correlate closely with clinical characteristics. The Streptococcus-dominated enterotype is associated with inflammation and appears to influence both the severity of illness during the acute phase and cardiopulmonary recovery. IMPORTANCE: This study sheds new light on the intricate process of rehabilitating the gut microbiota following disruptions caused by COVID-19. Our approach, which examines the dynamics from the vantage point of enterotypes, reveals a more rapid recovery than previously reported, with the majority of the microbiota rebounding within a 6-month timeframe. Furthermore, our findings underscore the importance of the Blautia-dominated enterotype as a marker of gut health, which plays a pivotal role in mitigating the risk of severe progression and lingering effects post-SARS-CoV-2 infection. By scrutinizing these enterotypes, we can now foresee the potential severity and aftermath of COVID-19, offering a valuable tool for prognosis and intervention.

8 January 2026 in Food & Function
Verified
Journal Article
Open access
PDF file
JNJiali Ni
Jiali Ni
JSJian Shen
Jian Shen
FWFengjiao Wang
Fengjiao Wang
YWYechen Wu
Yechen Wu
BQBo Qiu
Bo Qiu
LLLanjuan Li
Lanjuan Li
By gavage with Lactobacillus fermentum , it can alleviate the inflammatory response, regulate the microecological balance and metabolic environment in the lungs and gut, improve lung injury.

5 August 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
FWFengjiao Wang
Fengjiao Wang
YWYechen Wu
Yechen Wu
JNJiali NI
Jiali NI
QXQianhan Xie
Qianhan Xie
JSJian Shen
Jian Shen
LLLanjuan Li
Lanjuan Li
Gut microbiota dysbiosis has been observed in HBV-related cirrhosis, but its role in early-stage disease and its correlation with liver pathology remain unclear. Moreover, whether dysbiosis is a cause or consequence of liver cirrhosis is still debated. We recruited 20 treatment-naïve patients with chronic HBV infection, assessing liver injury via biopsy. Fecal metagenomic sequencing was used to analyze the correlation between gut microbiota and liver histology. To explore the causality, fecal samples from an HBV-related cirrhosis patient were transplanted into mice with CCl₄-induced liver fibrosis. Patients with significant histological damage exhibited reduced alpha diversity and greater microbial homogeneity. Species such as Eubacterium_sp_CAG_180 , Gemmiger_formicilis , and Oscillibacter_sp_ER4 had decreased abundance, while Parabacteroides_distasonis , Bacteroides_dorei , and Bacteroides_finegoldii were enriched. Mice receiving fecal transplants from the cirrhotic patient showed aggravated liver fibrosis, with increased collagen deposition; elevated ALT, AST, and ALP levels; and heightened hepatic inflammatory gene expression. Additionally, abnormal bile acid profiles with elevated unconjugated bile acids (e.g., GCA and CA) were observed. Gut microbiota dysbiosis is closely associated with liver histological damage in chronic HBV infection and may drive fibrosis progression via microbial-bile acid interactions. These findings suggest potential for gut microbiota-based assessment and treatment strategies in chronic hepatitis B. IMPORTANCE: This study elucidates a significant association between gut microbiota dysbiosis and liver histological damage in patients with chronic hepatitis B (HBV), potentially exacerbating fibrosis progression through bile acid interactions. By analyzing patient gut microbiota and conducting fecal transplant experiments in mice, researchers have identified that gut microbiota dysbiosis contributes to hepatic fibrosis during chronic HBV infection. These findings underscore the importance of the gut-liver axis in HBV disease progression, indicating that monitoring or modulating gut bacteria may facilitate early diagnosis or therapeutic interventions. This research bridges the gap in understanding whether microbial alterations drive disease progression or result from it, providing a foundation for developing therapies targeting the microbiome to mitigate liver damage in chronic HBV infections.

24 November 2025 in npj Science of Food
Verified
Journal Article
Open access
JNJiali Ni
Jiali Ni
FWFengjiao Wang
Fengjiao Wang
YWYechen Wu
Yechen Wu
JSJian Shen
Jian Shen
ZZZiyuan Zhou
Ziyuan Zhou
LLLanjuan Li
Lanjuan Li
The global burden of pulmonary fibrosis is increasing. Recent studies have shown that some pulmonary fibrotic lesions caused by COVID-19 infection may persist for a long time. Emerging evidence suggested a critical association between gut microbiota and pulmonary fibrosis. In this study, the clinical follow-up data from post-COVID-19 patients indicated that those with higher CT image scores were older, had a significantly lower Blautia and Bifidobacterium to Streptococcus ratio (B/S index). We examined whether Bifidobacterium adolescentis could attenuate bleomycin-induced pulmonary fibrosis in mice, with particular attention in the aging mice. Aging mice exhibited more severe pulmonary fibrosis after BLM induction, while the intervention of B. adolescentis attenuated the degree of pulmonary fibrosis in aging mice to a state similar to that of young mice. B. adolescentis alleviated inflammatory responses by enhancing the gut barrier, and reduced fibrotic marker expression (TGF-β, IL-17, α-SMA, Collagen I/III) by modulating PPAR and Th17 signaling pathways. Furthermore, B. adolescentis stabilized gut microbiota and increased the abundance of Bifidobacterium, Turicibacter, and norank_f_Desulfovibrionaceae, thereby suppressed the prostaglandin E2 (PGE2) and affected collagen deposition. B. adolescentis alleviates pulmonary fibrosis through the gut-lung axis by regulating PGE2/PPAR/Th17 signaling, providing a promising therapeutic approach for pulmonary fibrosis management.